Welcome to our dedicated page for LivaNova PLC SEC filings (Ticker: LIVN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
LivaNova PLC filings document the regulatory disclosures of an England and Wales public limited company with ordinary shares listed on Nasdaq under LIVN. Its Form 8-K reports primarily cover operating and financial results, earnings releases, business update calls, material events, and governance changes involving senior officers.
Proxy materials describe annual general meeting procedures, shareholder voting matters, director and governance proposals, and the company’s ordinary share structure. The filings also provide formal records for capital-structure disclosures and corporate governance matters relevant to LivaNova’s medical technology operations in neurological and cardiac conditions.
LivaNova PLC Chief Innovation Officer Ahmet Tezel exercised 12,692 Stock Appreciation Rights at a base price of $52.68 per share, receiving the same number of ordinary shares. In connection with this, 8,589 shares were withheld to pay the SARs base price, 1,428 shares were withheld to satisfy tax liability, and 2,675 shares were sold in open-market transactions at a weighted-average price of $77.7355, within a range of $77.6684–$77.7900. The SARs were granted on June 15, 2024, vest over four years from June 15, 2025, and expire on June 15, 2034.
LivaNova PLC reports a planned sale of 2,675 shares of common stock on or about 08/11/2026, arising from the exercise of employee stock appreciation rights. The shares are expected to be sold through Merrill Lynch in a broker assisted cashless exercise on NASDAQ for an aggregate value of $209,942.40.
FMR LLC filed a Schedule 13G reporting beneficial ownership of LivaNova PLC common stock. As of 06/30/2026, FMR LLC and Abigail P. Johnson each report beneficial ownership of 3,210,395.27 shares of LivaNova common stock, representing 5.8% of the outstanding class.
FMR LLC has sole voting power over 3,209,291.56 shares and sole dispositive power over 3,210,395.27 shares, with no shared voting or dispositive power. Abigail P. Johnson reports sole dispositive power over the same 3,210,395.27 shares and no voting power. One or more other persons may receive dividends or sale proceeds from these shares, but no such person has an interest exceeding five percent of the total outstanding common stock. Subsidiaries through which the securities are held are identified in an attached exhibit.
LivaNova PLC reported solid growth for the three and six months ended June 30, 2026. Net revenue was about $390.6 million for the quarter and $752.8 million year‑to‑date, up 10.8% and 12.5% from 2025, with contributions from both Cardiopulmonary and Neuromodulation across all regions.
Net income was about $108.6 million for the quarter and $130.9 million year‑to‑date, compared with $27.2 million and a $300.2 million loss a year earlier. Results reflect lower cost of sales as a percentage of revenue and a $95.4 million discrete Italian tax benefit related to the SNIA environmental liability.
Cash and cash equivalents were $516.6 million, and long‑term debt decreased to $289.9 million after full repayment of Term Facilities, leaving the 2.50% 2029 Notes as the primary borrowing. The balance sheet also carries sizeable obligations, including a $385.0 million SNIA environmental liability, $41.5 million Saluggia site provision, and $23.1 million 3T Heater‑Cooler litigation reserve.
LivaNova PLC executive Stefano Folli, President, Cardiopulmonary, reports initial beneficial ownership of 6,273 Restricted Stock Units (RSUs), each linked to one ordinary share. Granted on June 15, 2026, these RSUs vest 28% on March 30, 2027, 36% on March 30, 2028, and 36% on March 30, 2029, and are subject to forfeiture if vesting conditions are not met.
LivaNova PLC reported second‑quarter 2026 results with net revenue of $390.6 million, up 10.8% on a reported basis and 9.8% at constant currency versus 2025. Cardiopulmonary revenue rose to $221.6 million and Neuromodulation to $166.9 million, both delivering double‑digit growth.
GAAP net income was $108.6 million (diluted EPS $1.93) compared with $27.2 million ($0.50) a year earlier and included a discrete tax benefit of €81.8 million ($95.4 million) from a favorable Italian ruling on the SNIA environmental liability. Adjusted diluted EPS increased to $1.26 from $1.05, and adjusted operating income rose to $90.8 million from $77.4 million. Net cash from operating activities was $66.6 million, with adjusted free cash flow of $45.5 million.
LivaNova raised 2026 constant‑currency revenue growth guidance to 8%–9% and adjusted diluted EPS guidance to $4.30–$4.40, while lowering adjusted free cash flow guidance to $140–$160 million to fund Cardiopulmonary capacity, innovation, and IT investments. The company also announced a long‑term oxygenator‑component supply agreement with Thermo Fisher Scientific and several senior leadership appointments.
LivaNova PLC director Peter M. Wilver reported routine equity compensation activity involving restricted stock units (RSUs) and ordinary shares. On June 15, 2026, 4,042 RSUs vested and were settled into ordinary shares under the company’s 2025 Director Incentive Award Plan, and 486 ordinary shares were withheld to satisfy tax liabilities at a reference price of $79.70 per share. Following these transactions, he held 10,294 ordinary shares directly. On the same date, he received a new grant of 2,383 RSUs that each represent a right to receive one ordinary share and are scheduled to vest on June 15, 2027, subject to continued service and the plan terms. No open-market purchases or sales were reported.
LivaNova PLC director Todd C. Schermerhorn reported compensation-related equity activity involving restricted stock units (RSUs) and ordinary shares. On June 15, 2026, 4,042 RSUs were exercised into ordinary shares, and 486 shares were withheld at $79.70 per share to satisfy tax liabilities, leaving him with 12,619 ordinary shares directly owned.
On the same date, he received a new grant of 2,383 RSUs under LivaNova’s 2025 Director Incentive Award Plan, each representing a right to one ordinary share. These RSUs vest on June 15, 2027, subject to continued service and the plan’s terms. The tax withholding is an administrative disposition, not an open-market sale.
LivaNova PLC director Francesco Bianchi reported several equity transactions involving company ordinary shares and restricted stock units. He sold 1,200 ordinary shares in an open-market transaction at $80.19 per share and held 9,584 shares directly after the transactions. On the same date, vested restricted stock units were exercised, delivering 4,042 ordinary shares, with 486 shares withheld to satisfy tax liabilities at a price of $79.70 per share. Bianchi also received a new grant of 2,383 restricted stock units that each represent a right to receive one ordinary share, scheduled to vest on June 15, 2027 subject to continued service.